Financial Shenanigans

Figures converted from Japanese yen at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.

The Forensic Verdict

Tazmo's reported numbers are broadly faithful to economic reality, but the FY2024–FY2025 cash-flow surge — $47.8M and $59.6M of operating cash on $27.1M and $22.6M of net income — is mostly the unwind of two prior cash-burn years, not a structural step-up. The income statement shows no restatements, no accounting-policy changes, and no estimate revisions, and the balance sheet is conservatively financed (net cash, 56.6% equity ratio). The main forensic tensions are (1) working-capital normalisation flattering current CFO while order backlog has fallen from $250M to $125M, and (2) a segment redefinition effective FY2026 that absorbs the collapsing Coater line into Semiconductor equipment. The single data point that would most change this grade is the Yukashoken Hokokusho due March 23, 2026: auditor identity, audit-fee level, related-party tables, and any "emphasis-of-matter" language.

Grade: Watch (21–40). Multiple yellow flags around earnings smoothing through reserve and working-capital movements, plus a segment-reporting change that lines up with a product-line collapse. No red flags. No restatements, no auditor changes, no regulatory action found in public sources.

13-Shenanigan Scorecard

Breeding Ground

Tazmo's breeding-ground profile is structurally low-risk for a TSE Prime issuer of its size, with one or two judgement spots that the upcoming securities report will close. The Sustainability Committee, TCFD-aligned disclosure, and a "B" CDP score sit alongside a Prime-Market governance commitment to at least one-third independent directors. There is no founder-CEO concentration: the current president (Yasuyuki Sato) succeeded Toshio Ikeda, and the IR signatory (Hisao Yoshikuni) succeeded Shigeo Kameyama — two orderly transitions in the period covered. Aggregate director and officer compensation is essentially flat ($2.08M → $2.11M), and the entire share-award provision ($2.27M current + non-current) is roughly 1% of annual revenue — not the kind of equity-comp pool that creates aggressive-reporting pressure.

The breeding-ground gates closing in March 2026 are not academic. Five of the ten factors above are blocked until the Yukashoken Hokokusho lands. If the document arrives on schedule with a clean audit report, the breeding-ground risk drops from yellow-leaning to green; if it slips or contains an emphasis-of-matter, the score moves up.

Earnings Quality

Earnings quality is mixed: FY2024 record results were earned, but FY2025's reported operating margin compression (16.5% → 13.5%) was real and was partially cushioned by a one-time reversal of the doubtful-accounts allowance and a step-up in non-operating subsidy income. The income statement does not show evidence of revenue acceleration — quite the opposite, revenue was –1.2% and Q4 operating income collapsed to $2.2M (vs $12.9M in Q3). The cleaner question is whether reported numbers are being smoothed; the answer is "marginally yes, in the direction of slightly higher EBIT than a strict reading would support."

Revenue vs receivables and contract liabilities

Revenue fell –1.2% in FY2025 while total trade and electronic receivables fell –39.7% ($58.8M → $35.5M) and contract liabilities (customer prepayments / billings ahead of revenue) fell –30.3% ($33.5M → $23.3M). The directional signals are mutually consistent: large delivered projects were collected, fewer fresh orders are being booked, and customers are not pre-funding new programs at the prior pace. This is not "revenue stuffing" — if anything it is the opposite, with the balance-sheet evidence pointing at a slower order book ahead of reported revenue.

Doubtful-accounts allowance — the smoothing flag

FY2024 took a $604K charge into selling, general and administrative expense to provision for doubtful accounts. FY2025 reversed $65K as a credit to the same line. On a base of $30.4M operating income, the reversal is small (0.2%), but it is directionally an earnings-smoothing move: receivables fell 40%, yet the allowance came down only 11% ($604K → $540K), so the reserve as a percentage of gross receivables actually rose from 1.0% to 1.5% — meaning the income-statement credit understates how much reserve was technically released. Not a red flag in isolation; relevant only as part of the pattern with the FY2024 extraordinary "big-bath" items ($640K impairment + $280K securities loss + $210K extra retirement).

Capex / depreciation and operating-cost capitalisation

Capex has run ~1.5x depreciation through FY2025 — well within normal for a capacity-investing industrial. R-and-D expense ($4.67M FY2025) is fully expensed; software intangibles only $1.27M; there is no contract-asset or capitalised-customer-acquisition-cost line on the balance sheet. The clean flag here is the $43.9M FY2026 capex plan — a 5x step-up — which is a strategic bet on AI-driven advanced-packaging demand, not an accounting choice. Worth monitoring because under-utilised property, plant and equipment becomes impairment risk if the AI cycle slows.

Cash Flow Quality

CFO is real cash but not recurring at the FY2024–FY2025 run-rate. The five-year cash-conversion arc is the story: the $30M working-capital tailwind to FY2025 CFO is the mirror image of the build-up that should have been there during the FY2022–FY2023 cycle but was not.

CFO vs Net Income — five-year arc

Between FY2020 and FY2023, net income totalled $65.5M but CFO totalled just $10.7M — a $54.8M accumulated working-capital absorption. The FY2024–FY2025 period reverses $107.5M of CFO against $49.6M of net income, an excess of $57.9M that traces almost dollar-for-dollar back to that earlier inventory and receivables build. The 6-year cumulative is $115.2M net income against $118.1M CFO — a 1.03x ratio that is clean when viewed over the cycle, but misleading if a reader pegs FY2025's 2.64x as steady-state.

What's inside FY2025 CFO

Of the $59.6M of CFO, only $28.3M is underlying operating cash before working-capital changes (pretax income plus non-cash addbacks, plus interest and subsidies received, less interest and taxes paid: $31.95M + $6.21M + $1.25M + $1.63M − $0.54M − $12.20M = $28.30M). The remaining $31.3M is net working-capital release, dominated by inventory unwind and receivables collection on prior-year shipments. Strip the WC tailwind and FY2025 underlying CFO is roughly $28M — still solid but only 1.25x net income, not 2.64x. The next-cycle question is whether the working-capital release continues into FY2026 (CFO stays elevated as backlog drains) or reverses as the company rebuilds inventory against the $43.9M capex plan.

DSO, DIO, DPO — improvement is cyclical, not structural

The 86-day reduction in the cash-conversion cycle (318 → 232) looks like a textbook efficiency improvement. It is not. DSO compressed because receivables fell faster than revenue — i.e., the company collected on FY2024-shipped projects without booking equal-sized new ones. DIO compressed because work-in-process fell $27M as in-process projects were delivered. DPO compressed because the company paid down electronic payables by $12M — that is the opposite of a working-capital lifeline. Tazmo did not stretch suppliers to inflate CFO; it actually paid them faster. The integrity of the working-capital position is high; the durability of the resulting CFO is low.

Order backlog — the leading indicator that contradicts headline CFO strength

Backlog fell from $198M at FY2024 year-end to $125M at FY2025 year-end — a 37% YoY drop — and management's mid-FY2023 disclosure had shown a peak near $283M at end-FY2023 before the multi-quarter run-off. Combined with the $10M fall in contract liabilities (customer prepayments) and the Q4 FY2025 operating profit of $2.2M and Q1 FY2026 operating profit of $0.54M, the order book is signalling a sharp FY2026 H1 trough. None of this is forensic in the accounting sense — it is properly disclosed. The forensic implication is that anyone valuing the company off FY2024–FY2025 trailing CFO is paying for $20M+ of working-capital release that will not recur.

Metric Hygiene

Tazmo earns a green here. The company reports under Japanese GAAP only, with no parallel non-GAAP income statement, no adjusted EBITDA, no organic-growth metric, and no "billings ex-this", "ARR ex-that" constructs. The four reported profit lines — operating profit, ordinary profit, profit before income taxes, profit attributable to owners — reconcile cleanly to the cash-flow statement. There is one genuine yellow: the segment-reporting redefinition for FY2026 that combines Coater with Semiconductor equipment, eliminating the line that fell –65.5% in FY2025.

What to Underwrite Next

This name does not need a forensic discount, but it does need the analyst to read CFO in cycle-adjusted terms. Five specific items to track: